FDA Calls for Tighter Oversight of Infant Formula Ingredients

The U.S. Food and Drug Administration is asking the infant-formula industry to take a closer, more verifiable look at every supplier involved in powdered formula production. In a new FDA constituent update, the agency says recent public-health events show that contamination risks can enter through ingredients before a finished product reaches a factory or a family’s kitchen.

The request applies broadly to manufacturers, packagers, distributors, exporters, importers and retailers. The FDA’s central message is simple: companies need to know where their ingredients come from, how those ingredients are produced, what hazards they may carry and whether those hazards are being controlled effectively.

Why the FDA is focusing on the supply chain

The agency’s warning follows two multistate investigations involving infant botulism and powdered formula. The FDA says the investigations involved separate brands, ByHeart and Nara Organics, and led to voluntary recalls. In the ByHeart investigation, FDA inspections identified Clostridium botulinum in an organic whole-milk powder ingredient. The agency says two samples from one lot matched both a clinical sample and a formula sample through whole-genome sequencing. The investigation into the root cause remains ongoing.

The Nara Organics investigation also led to a recall of the company’s powdered infant formula. The FDA reports that the product used milk supplied by the same broader dairy supply chain involved in the ByHeart investigation, but it has not concluded that this proves the source or route of contamination. That distinction matters: the agency is identifying a supply-chain concern while continuing to investigate rather than presenting an unresolved link as a final finding.

The FDA also points to a separate international contamination event involving cereulide, a toxin produced by Bacillus cereus. Nearly 150 suspected and confirmed cases were reported across 10 countries during late 2025 and early 2026, and the event was traced to contaminated arachidonic acid oil used as an ingredient in infant formula. The FDA says the episode resulted in recalls in several countries and an import alert affecting products from an ARA oil supplier.

What manufacturers are expected to do

The agency’s accompanying letter to the infant-formula industry describes supplier oversight as part of the manufacturing process, especially when an ingredient will not receive a lethal treatment at the formula facility. Companies are expected to set ingredient specifications, quarantine ingredients that fail those specifications and use scheduled audits to verify suppliers’ current manufacturing and quality-control practices.

The letter also points to existing preventive-control obligations. Under the FDA’s framework, firms must analyse hazards, establish preventive controls and, where appropriate, maintain a risk-based supply-chain programme. Supplier verification can include qualified on-site audits for ingredients where a control is applied outside the formula manufacturer’s own facility.

The FDA is also reminding companies to treat recalls, outbreak investigations and import alerts as important safety signals. When a supplier or ingredient raises concerns, manufacturers are expected to assess the risk quickly and take appropriate action. The agency further highlights redundancy risk-management plans designed to identify and manage supply disruptions at formula-manufacturing establishments.

What this means for families preparing formula

The announcement is directed at industry rather than asking parents to perform laboratory checks at home. For caregivers, the practical message is to rely on current official information and follow the instructions for the specific formula being used. The FDA’s consumer guidance advises preparing formula according to the product label, cleaning and sanitising bottles and feeding equipment, and respecting the “Use By” date.

Families should also check the FDA’s infant-formula pages for active recalls or safety updates before using a product that has been recalled or when a safety alert changes. If a different formula is needed, the FDA advises discussing substitutions with the infant’s healthcare provider, particularly when a baby has a medical condition or uses a specialty formula. The agency also warns against homemade infant formula, which may lack essential nutrients and can introduce contamination risks in the home.

These steps do not replace the controls expected from manufacturers. Powdered formula is produced for a uniquely vulnerable population, and household preparation cannot correct a problem that entered through an ingredient or production environment. That is why the FDA’s latest action places responsibility on companies to verify suppliers before ingredients enter the manufacturing process and to respond quickly when warning signs appear.

What happens next

The FDA says it will continue investigating the causes of the recent infant-botulism outbreaks and assessing the presence of Clostridium botulinum in powdered milk. It is also working with scientific and international food-safety organisations on advice about spore-forming bacteria, environmental monitoring and stronger controls across the formula chain, including reconstitution.

The announcement does not declare that all powdered infant formula is unsafe, nor does it establish a new preparation method for consumers. Instead, it signals a stronger expectation that companies can demonstrate how their ingredients are controlled from supplier to finished product. For families, the most useful response is to keep following the label, maintain clean equipment and use official FDA recall information when checking the formula in the cupboard.